Regeneron Pharmaceuticals, Inc.

LSE:0R2M Stock Report

Market Cap: US$84.2b

Regeneron Pharmaceuticals Future Growth

Future criteria checks 2/6

Regeneron Pharmaceuticals is forecast to grow earnings and revenue by 8.1% and 6.9% per annum respectively. EPS is expected to grow by 8.6% per annum. Return on equity is forecast to be 15.2% in 3 years.

Key information

8.1%

Earnings growth rate

8.6%

EPS growth rate

Biotechs earnings growth37.2%
Revenue growth rate6.9%
Future return on equity15.2%
Analyst coverage

Good

Last updated14 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0R2M - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202615,8624,8875,9895,17221
12/31/202514,7574,2375,6325,17925
12/31/202414,1574,4235,3085,78625
9/30/202413,8474,6553,3194,247N/A
6/30/202413,4894,3223,1844,071N/A
3/31/202413,1003,8583,9304,739N/A
12/31/202313,1173,9543,6684,594N/A
9/30/202313,0973,9914,3595,224N/A
6/30/202312,6714,2993,0044,739N/A
3/31/202312,3704,1832,5274,281N/A
12/31/202212,1734,3383,3985,015N/A
9/30/202213,7105,3704,1485,668N/A
6/30/202214,2275,6877,8698,452N/A
3/31/202216,5087,9347,9368,515N/A
12/31/202116,0728,0756,5297,081N/A
9/30/202113,5436,9965,3815,940N/A
6/30/202112,3846,2051,6942,272N/A
3/31/20219,1984,0042,0292,589N/A
12/31/20208,4973,5132,0042,618N/A
9/30/20207,9383,1561,5822,175N/A
6/30/20207,3872,9842,4252,986N/A
3/31/20207,0132,2791,7062,231N/A
12/31/20196,5582,1162,0002,430N/A
9/30/20196,6222,1441,9952,371N/A
6/30/20196,5422,0691,9062,267N/A
3/31/20196,5722,4282,0952,473N/A
12/31/20185,1462,4441,8122,195N/A
9/30/20186,3651,7981,6282,033N/A
6/30/20186,2031,591N/A1,995N/A
3/31/20186,0651,428N/A1,570N/A
12/31/20175,8721,199N/A1,307N/A
9/30/20175,5171,278N/A1,118N/A
6/30/20175,2361,155N/A1,354N/A
3/31/20174,979963N/A1,784N/A
12/31/20164,860896N/A1,486N/A
9/30/20164,732797N/A1,377N/A
6/30/20164,649743N/A1,619N/A
3/31/20164,435741N/A1,477N/A
12/31/20154,104636N/A1,331N/A
9/30/20153,808571N/A1,247N/A
6/30/20153,396444N/A519N/A
3/31/20153,063346N/A597N/A
12/31/20142,820338N/A752N/A
9/30/20142,628345N/A831N/A
6/30/20142,499403N/A759N/A
3/31/20142,291394N/A551N/A
12/31/20132,105414N/A589N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0R2M's forecast earnings growth (8.1% per year) is above the savings rate (2.1%).

Earnings vs Market: 0R2M's earnings (8.1% per year) are forecast to grow slower than the UK market (14.7% per year).

High Growth Earnings: 0R2M's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0R2M's revenue (6.9% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0R2M's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0R2M's Return on Equity is forecast to be low in 3 years time (15.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y